André Warnke

André Warnke is the Managing Director of SocraMetrics GmbH. Together with Juliana Brudel, he took over from Dr. Barbara Schug in 2022. His career began over 20 years ago in clinical research at our sister company SocraTec R&D GmbH. He headed the monitoring and project management departments there until 2012, before moving to SocraTec R&D’s management. In 2022, he then joined the management of SocraMetrics.

André Warnke is characterised by openness, scientific curiosity, sound judgement, and a long-standing commitment to clinical research and the SocraGroup family. His ability to make well-considered decisions and act strategically makes him the ideal leader for both companies.

In these roles, André Warnke has led numerous Phase I and IIa/b studies, including those with special populations/patients, IVIVC and PK/PD studies, and drug-drug interaction studies. His expertise includes the clinical development of complex drugs such as TTS (transdermal therapeutic systems), OIPs (orally inhaled drug products), and LAIs (long-acting injectable drugs) as well as generics. His work particularly focuses on studies in the early phases of clinical development and clinical research in the areas of women's health, metabolic diseases, dermatology, pain management, ophthalmology, and clinical development in OTC (over-the-counter) and self-medication indications.

In addition, André Warnke is interested in digital health, digital endpoints, the development of value-added generics, and early-stage development methodologies.

André Warnke is a member of several scientific societies and has been active on the board of the Association for Applied Human Pharmacology (Arbeitsgemeinschaft für Angewandte Humanpharmakologie e.V. - AGAH) as treasurer since 2024.